Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
复制标题
DOI：
10.2217/imt.10.20
复制
发表时间：
2010-05
期刊：
影响因子：
2.8
通讯作者：
Murphy WJ
中科院分区：
文献类型：
--
作者：
Bouchlaka MN;Redelman D;Murphy WJ
造血干细胞移植（HSCT）是治疗血液系统恶性肿瘤的一种特别重要的方法。不幸的是，在同种异体HSCT之后，移植物抗宿主病、免疫抑制和对机会性感染的易感性仍然是限制该程序的功效和使用的最实质性问题，特别是对于癌症。免疫疗法和/或移植物的操作提供了攻击残留癌症以及其他移植相关并发症的方法。最近令人兴奋的发现表明，HSCT可以扩展到实体组织癌症，对过继免疫治疗的有效性产生深远影响。这篇综述将提供有关HSCT的背景，讨论并发症，使其成为一个复杂的治疗程序，目前的免疫治疗策略，并讨论在HSCT中应用免疫治疗癌症的新兴方法。
Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.